PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Blue Cross & Blue Shield of MississippiAll Plans · Prior Auth · Medical Policy · Dermatology, Pulmonology, Allergy & Immunology +2 moreMedium impact

Dupixent (dupilumab)

Effective date
Oct 1, 2025
Identified
Jun 20, 2026

Summary

Already effective 2025-10-01: the initial and renewal criteria were updated for moderate-to-severe atopic dermatitis, moderate-to-severe asthma, COPD, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis and prurigo nodularis, and the initial length of approval changed from 6 months to 12 months. Prior authorization is required, and the use of samples by an individual will not be considered current or stable therapy to satisfy policy requirements. Dupixent (dupilumab) will be obtained through a BCBSMS network DSP-pharmacy.

Get alerts when payers change rules like this one

We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.

Get Blue Cross & Blue Shield of Mississippi alertsPolicy Monitoring is free. No card required.

What to do

Action · 7 steps
01Billing team: Get prior authorization before billing Dupixent, because prior authorization is required.
02Confirm the individual meets the initial criteria for the diagnosis being treated, and that the prescriber has assessed and documented baseline pruritus and other symptom severity for atopic dermatitis.
03Confirm the prescribed dosage is within the program quantity limit based on the FDA-approved labeled dosage.
04Do not document sample use as current or stable therapy.
05For renewals, the individual must have been previously approved through the BCBSMS prior authorization process.
06Medication trials and adherence are determined from pharmacy claims data over the preceding twelve months, and medical records from the provider that list previously prescribed medications will not be sufficient to show them.
07Initial approval lasts 12 months.

Codes mentioned

C9399J3590

Original notice

Dupixent (dupilumab)
bcbsms.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account